Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Kimihiko KatoToyoaki Murohara

Abstract

The aim of this study was to evaluate the role of matrix metalloproteinases (MMPs) for the prediction of long-term maintenance of sinus rhythm (SR) after cardioversion in atrial fibrillation (AF). The study comprised 102 patients with AF. Pharmacological cardioversion was attempted for a 4-week period with anti-arrhythmic drugs in all patients. Those who failed medication underwent electrical cardioversion. Blood samples for biomarkers and echocardiographic data were obtained at baseline. Thirty-four patients (33.3%) converted to SR by pharmacological (n = 22) and electrical (n = 12) cardioversion and maintained it (SR group). The remaining 68 patients were refractory to the AF (RAF) group including recurrence (n = 22) and unsuccessful treatment (n = 46) after electrical/pharmacological cardioversion. Refractory AF was significantly associated with the duration of AF, hypertension, left atrial diameter, brain natriuretic peptide, MMP-2, and tissue inhibitor of MMP-2. For both multivariable logistic regression analysis and stepwise forward selection procedure, the duration of AF >5 months [odds ratio (OR) 15.32] and MMP-2 >767.0 ng/mL (OR 4.84) were significantly associated with RAF. Our study suggests that elevated MMP-2 and lo...Continue Reading

References

Apr 29, 1982·The New England Journal of Medicine·W B KannelP M McNamara
Dec 24, 1997·Clinical and Experimental Pharmacology & Physiology·C P Lau, H F Tse
Jun 14, 2002·Cardiovascular Research·Sawa KostinJutta Schaper
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Nov 19, 2003·Circulation·Ronnier J AvilesMina K Chung
Oct 4, 2005·Journal of the American College of Cardiology·Joseph F MaloufVirend K Somers
Sep 16, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Isabelle C Van Gelder, Martin E W Hemels
Jul 12, 2008·Journal of the American College of Cardiology·Eleftherios M KallergisPanos E Vardas

❮ Previous
Next ❯

Citations

Jul 5, 2011·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Joachim R EhrlichStefan H Hohnloser
Nov 16, 2010·Cardiovascular Research·Anne Margreet De JongIsabelle C Van Gelder
Jan 13, 2012·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Marcelle D SmitIsabelle C Van Gelder
Nov 20, 2013·Cardiology·Christopher KnutsonAdam S Budzikowski
Aug 27, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Koichi NagashimaAtsushi Hirayama
Nov 2, 2012·Journal of Cardiovascular Medicine·Enrico VizzardiLivio Dei Cas
Mar 13, 2014·Heart, Lung & Circulation·Takehiro KimuraKeiichi Fukuda
Apr 15, 2015·Annales de cardiologie et d'angéiologie·J LewkowiczW J Musiał
Jul 9, 2016·International Journal of Cardiology·Gordon A BeggMuzahir H Tayebjee
Dec 19, 2013·The Journal of International Medical Research·Mingjiang LiCongxin Huang
May 16, 2018·Herzschrittmachertherapie & Elektrophysiologie·Jelena KornejGerhard Hindricks
Mar 21, 2018·Current Medicinal Chemistry·Dimitris TsiachrisChristodoulos Stefanadis
Sep 20, 2017·Current Medicinal Chemistry·Polychronis DilaverisDimitris Tousoulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.